Antibacterial Efficacy of Curcumin against Multidrug- Resistant Bacteria Isolated from Diabetic Foot Infections: An In Vitro Study

Abstract Background Diabetic foot infection (DFI) represents a major global clinical challenge, frequently complicated by the emergence of multidrug-resistant (MDR) bacterial pathogens. Curcumin, a natural polyphenolic compound derived from Curcuma longa , possesses broad-spectrum antimicrobial activity; however, its specific efficacy against clinical MDR pathogens isolated exclusively from DFIs remains insufficiently evaluated. This study aimed to investigate the in vitro antibacterial activity of Curcumin against MDR bacterial strains isolated from infected diabetic foot ulcers. Methods A total of 54 non-duplicate bacterial isolates were recovered from 30 patients presenting with clinically infected DFIs at a tertiary care center. Species identification was performed using standard biochemical testing and confirmed via the VITEK 2 Compact automated system. Antimicrobial susceptibility testing was conducted using the disk diffusion method according to Clinical and Laboratory Standards Institute (CLSI M100) guidelines. Minimum inhibitory concentrations (MICs) of curcumin (0.5–512 ug/mL) were determined using the broth microdilution technique. Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 25922 served as quality control strains. Results The isolates comprised Staphylococcus aureus (n = 25, 46.3%), Klebsiella pneumoniae (n = 15, 27.8%), Pseudomonas aeruginosa (n = 8, 14.8%), Acinetobacter baumannii (n = 4, 7.4%), and Enterobacter cloacae (n = 2, 3.7%). All 54 isolates exhibited an MDR phenotype. Curcumin demonstrated consistent antibacterial activity against all tested isolates, with MICs ranging from 32 to 128 ug/mL. Gram-positive isolates ( S. aureus ) displayed two-fold higher susceptibility (MIC range: 32–64 ug/mL) compared to Gram-negative species (64–128 ug/mL). Carbapenem-resistant non-fermenting bacilli ( P. aeruginosa and A. baumannii ) exhibited MICs of 128 ug/mL. Conclusions Curcumin exhibits robust in vitro activity against MDR pathogens isolated from DFIs at concentrations achievable via modern topical formulations. These findings warrant further investigation into bio-enhanced topical vehicles and controlled clinical trials to evaluate its potential as an adjunctive antimicrobial strategy in DFI management.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-12
DOI
https://doi.org/10.21203/rs.3.rs-11690651/v1
Primary Topic
Curcumin's Biomedical Applications
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Antibacterial Efficacy of Curcumin against Multidrug- Resistant Bacteria Isolated from Diabetic Foot Infections: An In Vitro Study

Thualfakar Hayder Hasan, Wurood Kadhim Abd, Ahmed Alshammari
Research Square
Curcumin's Biomedical Applications
preprint

Antibacterial Efficacy of Curcumin against Multidrug- Resistant Bacteria Isolated from Diabetic Foot Infections: An In Vitro Study

Thualfakar Hayder Hasan, Wurood Kadhim Abd, Ahmed Alshammari
preprint en

Abstract

Abstract Background Diabetic foot infection (DFI) represents a major global clinical challenge, frequently complicated by the emergence of multidrug-resistant (MDR) bacterial pathogens. Curcumin, a natural polyphenolic compound derived from Curcuma longa , possesses broad-spectrum antimicrobial activity; however, its specific efficacy against clinical MDR pathogens isolated exclusively from DFIs remains insufficiently evaluated. This study aimed to investigate the in vitro antibacterial activity of Curcumin against MDR bacterial strains isolated from infected diabetic foot ulcers. Methods A total of 54 non-duplicate bacterial isolates were recovered from 30 patients presenting with clinically infected DFIs at a tertiary care center. Species identification was performed using standard biochemical testing and confirmed via the VITEK 2 Compact automated system. Antimicrobial susceptibility testing was conducted using the disk diffusion method according to Clinical and Laboratory Standards Institute (CLSI M100) guidelines. Minimum inhibitory concentrations (MICs) of curcumin (0.5–512 ug/mL) were determined using the broth microdilution technique. Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 25922 served as quality control strains. Results The isolates comprised Staphylococcus aureus (n = 25, 46.3%), Klebsiella pneumoniae (n = 15, 27.8%), Pseudomonas aeruginosa (n = 8, 14.8%), Acinetobacter baumannii (n = 4, 7.4%), and Enterobacter cloacae (n = 2, 3.7%). All 54 isolates exhibited an MDR phenotype. Curcumin demonstrated consistent antibacterial activity against all tested isolates, with MICs ranging from 32 to 128 ug/mL. Gram-positive isolates ( S. aureus ) displayed two-fold higher susceptibility (MIC range: 32–64 ug/mL) compared to Gram-negative species (64–128 ug/mL). Carbapenem-resistant non-fermenting bacilli ( P. aeruginosa and A. baumannii ) exhibited MICs of 128 ug/mL. Conclusions Curcumin exhibits robust in vitro activity against MDR pathogens isolated from DFIs at concentrations achievable via modern topical formulations. These findings warrant further investigation into bio-enhanced topical vehicles and controlled clinical trials to evaluate its potential as an adjunctive antimicrobial strategy in DFI management.

Research Square
Jabir Ibn Hayyan University for Medical and Pharmaceutical Sciences (IQ)
Good health and well-being
Curcumin's Biomedical Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon